Evidence map›Paper›PMID 41774910›Full record

ReviewAmerican journal of clinical pathology2026

Elucidating the grading intricacies of idiopathic multicentric Castleman disease histopathology: a pathologist's perspective.

Daisy V Alapat, Payam Etebari, Frits Van Rhee

Erratum issuedAbstract readReview
In one paragraph

Review in American journal of clinical pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Daisy V AlapatDepartment of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, United States.ORCID 0000-0002-3414-8375
Payam EtebariRecordati Rare Diseases, Bridgewater, NJ, United States.ORCID 0009-0004-5301-434X
Frits Van RheeMyeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR, United States.ORCID 0000-0001-9959-1282

Funding

Recordati Rare Diseases Inc
6 · The paper itself

Abstract

objectiveIdiopathic multicentric Castleman disease (iMCD) is a rare condition with a wide range of signs and symptoms that often overlap with other conditions that cause lymphadenopathy. The diagnosis of iMCD remains challenging, even among experts. Our aim is to highlight the heterogeneity of histopathologic features and presentations of iMCD and to provide tools to help diagnose and raise awareness of this rare condition.

methodsWe review the most relevant clinicopathologic aspects of iMCD and present our process to accurately diagnose this condition using a case-based approach. We describe how to incorporate the iMCD diagnostic criteria, including grading of histomorphology, laboratory, and clinical findings.

resultsHere, we describe our system to grade histopathologic features in iMCD. Together with radiologic findings and laboratory and clinical information, this system helps clinicians accurately identify iMCD and its subtypes, leading to more appropriate and timely diagnosis and treatment.

conclusionsThe diagnosis of iMCD can be challenging and requires a multidisciplinary team of hematologists, pathologists/hematopathologists, and other specialists. There is a pressing and unmet clinical need for a harmonized system to grade the histopathologic features of iMCD. This condition should be included in the differential diagnosis when other causes of a lymphoproliferative disorder (eg, infections, autoimmune/inflammatory disorders, malignancy) have been ruled out.

Indexed as

Castleman DiseaseDiagnosis, DifferentialHumansLymph Nodesdiagnosisgradinghistopathologyidiopathic multicentric Castleman disease

Identifiers

PMID41774910
PMCPMC13010271

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.